Zhifei Biological's Freeze-Dried Rabies Vaccine Trial Application Accepted by NMPA
Zhifei Biological announced on September 1 that its wholly-owned subsidiary Anhui Zhifei Longcom Biopharmaceutical received acceptance from China's National Medical Products Administration for its clinical trial application of a freeze-dried human rabies vaccine (ZFB-3 cells). If no objections are raised within 60 days, the subsidiary may proceed with trials as proposed.
Zhifei Biological announced on September 1 that its wholly-owned subsidiary, Anhui Zhifei Longcom Biopharmaceutical Co. , Ltd. , has received an acceptance notice from the National Medical Products Administration (NMPA) for its drug clinical trial application for a freeze-dried human rabies vaccine (ZFB-3 cells).
If the Center for Drug Evaluation does not issue a negative or questioning opinion within 60 days from the date of acceptance, Zhifei Longcom may proceed with the clinical trial according to the submitted protocol.